Joint Clinical Trials Office

CT Open to Enrollment

A Phase 1b/2, Multicenter, Randomized, Open-Label Study to Evaluate The Efficacy And Safety Of GSK5764227 Alone And In Combination In Participants With Previously Treated Advanced Unresectable Or Metastatic Gastrointestinal Solid Tumors

This clinical trial is for adults who have been diagnosed with advanced or metastatic colorectal cancer (CRC) OR advanced or metastatic pancreatic cancer (PDAC).

A Phase 1 study of BAL0891 as monotherapy and in combination with chemotherapy in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia

The purpose of this study is to evaluate the safety and effectiveness of BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel in patients with advanced solid tumors or relapsed or refractory acute myeloid leukemia.
   
In this study BAL0891, tislelizumab and paclitaxel will be given intravenously (meaning through a needle in the vein directly into the blood). 
   
Total length of participation in this research will vary depending on disease status.

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician’s Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma

 This clinical trial is for men and women with returned (relapsed) and/or has not responded to previous treatments (refractory) Peripheral T cell Lymphoma, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma.
   
The purpose of this study is to evaluate the safety and effectiveness of an investigational drug soquelitinib versus standard of care treatments. Investigational means that soquelitinib has not been approved by the U.S. Food and Drug Administration (FDA).
   

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

This clinical trial is for men and women with Secondary Hemophagocytic Lymphohistiocytosis (sHLH) to evaluate the safety and effectiveness of ELA026.
   
In this study, ELA026 will be given intravenously (meaning through a needle in the vein directly into the blood).
   
Participation is expected to last about 3 years. Participants will be admitted to the hospital at the start of the study during the administration of ELA026.

A Phase II Trial of Durvalumab with Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma

The purpose of this study is to test the good and bad effects of the drug called durvalumab in combination with the chemotherapy drugs gemcitabine and cisplatin. We are doing this study because we want to find out if this approach is better or worse than the usual approach for liver cancer.

The combination of gemcitabine, cisplatin, and durvalumab has been approved by the U.S. Food and Drug Administration (FDA) as front line therapy for advanced biliary tract cancers, including intrahepatic cholangiocarcinoma.

A Randomized Phase 2 Trial of ASTX727 +/- Iadademstat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

This trial compares the effect of ASTX727 in combination with iadademstat to ASTX727 alone in treating patients with accelerated or blast phase Philadelphia chromosome negative myeloproliferative neoplasms (MPNs).

BIO89-100-131: A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis

The purpose of this study is to test if an investigational study drug, pegozafermin, is safe and effective in treating patients with MASH metabolic dysfunction-associated steatohepatitis (MASH).

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Clinical Study to Assess Efficacy and Safety of Ropeginterferon alfa-2b (P1101) in Adult Patients with Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis

The purpose of this study is to determine if investigational Ropeginterferon alfa-2b-njft (P1101) is safe and effective at treating participants with pre-fibrotic/early primary myelofibrosis.

Investigational means that Ropeginterferon alfa-2b-njft (P1101) is not approved by the U.S. Food and Drug Administration.

Experiences of individuals who have participated in Crystal Meth Anonymous: a qualitative study

The purpose of this study is to learn about people’s experiences with Crystal Meth Anonymous (CMA), a 12-step community-based support group for people who use crystal methamphetamine. 

Tirzepatide’s Role in Postmenopausal HR+ Breast Cancer Survivors

This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal women with a history of hormone receptor-positive breast cancer and obesity.

The investigators aim to understand whether participants are willing and able to take this medication once weekly via subcutaneous injection for 6 months and whether it may help improve weight and overall health.